Cargando…
Handbook of targeted cancer therapy /
Make optimal use of the latest personalized therapeutic strategies with Handbook of Targeted Cancer Therapy! This concise, practical oncology reference examines more than 120 targeted therapy agents for which clinical trial data are available, and explains when and how you can use them to most effec...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Philadelphia :
Wolters Kluwer Health,
©2015.
|
| Edición: | 1st ed. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Ma 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn904377433 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 140722s2015 paua obf 001 0 eng d | ||
| 040 | |a OTZ |b eng |e pn |c OTZ |d OCLCO |d EBLCP |d OCLCF |d OCLCQ |d YDX |d N$T |d OCLCO |d UAB |d OCLCO |d OCLCA |d D6H |d OCLCO |d AGLDB |d OCLCO |d IGB |d OCLCO |d CN8ML |d SNK |d INTCL |d OCLCO |d MHW |d BTN |d AUW |d OCLCQ |d VTS |d OCLCQ |d OCLCO |d AU@ |d G3B |d S8I |d S8J |d S9I |d STF |d LOA |d MERUC |d SCB |d OCLCO |d VT2 |d USU |d OCLCO |d OCLCQ |d OCLCA |d OCLCQ |d OCLCA |d VLY |d DKU |d YDXCP |d QGK |d OCL |d OCLCO |d OCLCQ |d OCLCO |d ELBRO |d OCLCQ |d OCLCO |d OCLCL | ||
| 016 | 7 | |a 101637430 |2 DNLM | |
| 019 | |a 899359538 |a 987351660 |a 987738124 |a 1072012677 |a 1103263051 |a 1162302923 |a 1228572739 | ||
| 020 | |a 9781451193268 |q (alk. paper) | ||
| 020 | |a 1451193262 |q (alk. paper) | ||
| 020 | |a 9781469894584 | ||
| 020 | |a 1469894580 | ||
| 020 | |z 1451193262¡ | ||
| 029 | 1 | |a AU@ |b 000062429640 | |
| 035 | |a (OCoLC)904377433 |z (OCoLC)899359538 |z (OCoLC)987351660 |z (OCoLC)987738124 |z (OCoLC)1072012677 |z (OCoLC)1103263051 |z (OCoLC)1162302923 |z (OCoLC)1228572739 | ||
| 050 | 4 | |a RC271.C5 |b H36 2015 | |
| 050 | 4 | |a RC271.C5 | |
| 060 | 4 | |a QZ 39 |b H23658 2015 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.99/4061 |2 23 |
| 082 | 0 | 4 | |a RC271.C5 |2 23 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Handbook of targeted cancer therapy / |c editors, Daniel D. Karp, Gerald S. Falchook ; assistant editor, Johnique T. Atkins. |
| 246 | 3 | |a Targeted cancer therapy | |
| 250 | |a 1st ed. | ||
| 260 | |a Philadelphia : |b Wolters Kluwer Health, |c ©2015. | ||
| 300 | |a 1 online resource (xix, 287 pages) : |b color illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Handbook of Targeted Cancer Therapy; Contributors; Preface; Acknowledgments; Contents; Section 1 Targets by Organ Site; Abbreviations; Adrenocortical Carcinoma; Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct); Bladder Carcinoma (Urothelial Cancer); Brain Tumors; Glioblastoma/Malignant Gliomas; Medulloblastoma; Meningiomas; Other NF-Related Tumors; Breast Cancer; ER/PR+; HER2+; Triple-Negative/Basal/Metaplastic; Cervical Cancer; Colorectal Cancer (Adenocarcinoma); Esophageal Cancer (Squamous Cell); Gastric Cancer/Gastroesophageal Junction (Adenocarcinoma); Head and Neck Cancer. | |
| 505 | 8 | |a Squamous Cell-OropharynxSalivary Gland; Kidney (Renal Cell) Cancer; Liver Cancer (Hepatocellular); Leukemia; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Neoplasm; Lung Cancer (Non-Small Cell); Lymphoma; Melanoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer (Ductal Carcinoma); Prostate Cancer (Adenocarcinoma); Sarcoma (Gastrointestinal Stromal Tumors, GIST); Skin Cancer (Basal Cell); Testicular Cancer (Germ Cell Carcinoma); Thymoma and Thymic Carcinoma; Thyroid Cancer. | |
| 505 | 8 | |a Papillary and Follicular CarcinomaMedullary Carcinoma; Anaplastic Carcinoma; Uterine (Endometrial) Cancer; Section 2 Carcinogenesis from the Perspective of Targeted Therapy; Section 3 Molecular Targets and Pathways; Angiogenesis; Angiogenesis Regulators; Targeting HIF-1Ü; Receptor Tyrosine Kinases; VEGFR and Targeting VEGFR; FGFR and Targeting FGFR; PDGFR and Targeting PDGFR; TIE Receptors Signaling; TIE Receptors; IGF-1R and Insulin Receptor Signaling; IGF-1R and Insulin Receptor; TGFÜ/Ý Pathway; EGFR Family of Receptors; EGFR Ligands; EGFR Resistant and Sensitive Mutations; EGFR Inhibition. | |
| 505 | 8 | |a Targeting HER2HGF Receptors: MET; Targeting MET; RET Receptor; Targeting RET; KIT Receptor; ALK Receptor; ALK Alterations; G Protein-Coupled Receptor Pathways; RAS/MAPK Pathway; Targeting RAS; Targeting BRAF Mutations; Targeting MEK and MAPK; PI3K Pathway; Targeting PI3K Mutations; AKT Pathway; Targeting AKT Mutations; PTEN Alterations and TSC Mutations; Targeting mTORC1 Complex; Targeting mTORC2 Complex; JAK/STAT Pathway; Targeting JAK; Hedgehog Signaling Pathway; Notch Pathway; Wnt Pathway; SRC Pathway; NFmB Pathway; Death Receptors and Apoptosis; Cell Cycle Regulation; TP53; RB1. | |
| 505 | 8 | |a CDKN2A RegulationBRCA; BRCA and PARP; Aurora Kinases; Immunotherapy; Section 4 Targeted Therapy Agents; Abiraterone Acetate (Zytiga); ABT-199; Afatinib Dimaleate (Gilotrif); Afuresertib; Alemtuzumab (Campath-1h); Alisertib; Amg 208 and 337; Apatinib; Axitinib (Inlyta); Anetumab Ravtansine; Bevacizumab (Avastin); BI 811283; Bicalutamide (Casodex/Cosudex); Blinatumomab; BMS-936559; Bortezomib (Velcade); Bosutinib (Bosulif); Brentuximab Vedotin (Adcetris); Brivanib Alaninate; Buparlisib; BYL719; Cabozantinib (Cometriq); Carfilzomib (Kyprolis); Cediranib; Cetuximab (Erbitux); Cixutumumab. | |
| 520 | 8 | |a Make optimal use of the latest personalized therapeutic strategies with Handbook of Targeted Cancer Therapy! This concise, practical oncology reference examines more than 120 targeted therapy agents for which clinical trial data are available, and explains when and how you can use them to most effectively combat cancer. Approach clinical challenges from any direction with separate sections on Targets by Organ Site, Carcinogenesis from the Perspective of Targeted Therapy, Molecular Targets and Pathways, and Targeted Therapy Agents; find information easily thanks to a color-coded format and an intuitive organization; access the complete contents online and on mobile devices, with regular updates to include newly approved treatments and important state of the art cancer information for caregivers, researchers, other health care professionals, and even patients. Now with the print edition, enjoy the bundled interactive eBook edition, offering tablet, smartphone, or online access to: complete content with enhanced navigation; a powerful search tool that pulls results from content in the book, your notes, and even the web; cross-linked pages, references, and more for easy navigation; highlighting tool for easier reference of key content throughout the text; ability to take and share notes with friends and colleagues and quick-reference tabbing to save your favorite content for future use. | |
| 546 | |a English. | ||
| 590 | |a eBooks on EBSCOhost |b EBSCO eBook Subscription Academic Collection - Worldwide | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Cancer |x Chemotherapy |v Handbooks, manuals, etc. | |
| 650 | 0 | |a Antineoplastic agents |v Handbooks, manuals, etc. | |
| 650 | 0 | |a Drug targeting |v Handbooks, manuals, etc. | |
| 650 | 0 | |a Cancer |x Molecular aspects |v Handbooks, manuals, etc. | |
| 650 | 1 | 2 | |a Molecular Targeted Therapy |x methods |
| 650 | 1 | 2 | |a Neoplasms |x drug therapy |
| 650 | 2 | 2 | |a Antineoplastic Agents |x administration & dosage |
| 650 | 2 | 2 | |a Antineoplastic Agents |x antagonists & inhibitors |
| 650 | 2 | 2 | |a Antineoplastic Agents |x metabolism |
| 650 | 6 | |a Cancer |x Chimiothérapie |v Guides, manuels, etc. | |
| 650 | 6 | |a Anticancéreux |v Guides, manuels, etc. | |
| 650 | 6 | |a Médicaments |x Ciblage |v Guides, manuels, etc. | |
| 650 | 6 | |a Cancer |x Aspect moléculaire |v Guides, manuels, etc. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Antineoplastic agents |2 fast | |
| 650 | 7 | |a Cancer |x Chemotherapy |2 fast | |
| 650 | 7 | |a Cancer |x Molecular aspects |2 fast | |
| 650 | 7 | |a Drug targeting |2 fast | |
| 650 | 7 | |a Therapie |2 gnd | |
| 650 | 7 | |a Immuntherapie |2 gnd | |
| 650 | 7 | |a Krebs |g Medizin |2 gnd | |
| 650 | 7 | |a Onkologie |2 gnd | |
| 655 | 2 | |a Handbook | |
| 655 | 7 | |a manuals (instructional materials) |2 aat | |
| 655 | 7 | |a handbooks. |2 aat | |
| 655 | 7 | |a Handbooks and manuals |2 fast | |
| 655 | 7 | |a Handbooks and manuals. |2 lcgft | |
| 655 | 7 | |a Guides et manuels. |2 rvmgf | |
| 700 | 1 | |a Karp, Daniel D., |e editor. | |
| 700 | 1 | |a Falchook, Gerald S., |e editor. | |
| 700 | 1 | |a Atkins, Johnique T., |e editor. | |
| 758 | |i has work: |a Handbook of targeted cancer therapy and immunotherapy (Text) |1 https://id.oclc.org/worldcat/entity/E39PCGgWVtWWGGd88Pdd4MfgJC |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t Handbook of targeted cancer therapy. |b 1st ed. |d Philadelphia : Wolters Kluwer Health, ©2015 |z 9781451193268 |w (DLC) 2014028967 |w (OCoLC)884541294 |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=2035698 |z Texto completo |
| 938 | |a eLibro |b ELBO |n ELB167605 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL2035698 | ||
| 938 | |a EBSCOhost |b EBSC |n 1473100 | ||
| 938 | |a YBP Library Services |b YANK |n 13519248 | ||
| 938 | |a YBP Library Services |b YANK |n 12399329 | ||
| 994 | |a 92 |b IZTAP | ||